科瑞产品

- 客户定制产品 - 前列腺素系列 - PI3K Inhibitors - C-Kit Inhibitors - VEGFR Inhibitors - mTOR Inhibitors - c-Met Inhibitors - DNA/RNA Inhibitors - HER2 Inhibitors - Raf Inhibitors - JAK Inhibitors - Others - SRC Inhibitors - AKT Inhibitors - CDK Inhibitors

浙江省台州市椒江开发大道东段288号万达广场2号楼

0576-88813233

0576-88670057

sales@crene.cn

合作客户/Partner

当前位置：科瑞产品

RVT-501（E6005）

规格	价格	库存	数量
在线咨询大包装询价加入购物车

如您需要更多数量的报价，请点击立即获取报价或者通过电子邮件sales@crene.cn把您需要的数量信息提交给我们我们会在第一时间回复您，谢谢！

产品信息

产品名称：RVT-501（E6005）	纯度：98%min
CAS NO：947620-48-6	溶解度：Soluble in DMSO
分子式：C₂₆H₂₄N₄O₅	包装：可按客户要求包装。
分子量：472.49	贮存：Store at -20℃ 3 years

质量控制

备注说明

RVT-501 (E6005) is a selective phosphodiesterase 4 (PDE4) inhibitor with an IC₅₀ of 2.8 nM.RVT-501 potently and selectively inhibits human PDE4 activity with an IC₅₀ of 2.8 nM and suppresses the production of various cytokines from human lymphocytes and monocytes with IC₅₀ values ranging from 0.49 to 3.1 nM^[1].RVT-501 is currently in phase 2 development for patients with mild-to-moderate atopic dermatitis. In mice models, the topical application of RVT-501 produces an immediate antipruritic effect as well as an anti-inflammatory effect with reduced expression of cytokines/adhesion molecules. On the basis of these observed effects, topical RVT-501 ameliorates the appearance of atopic dermatitis-like skin lesions in two types of AD models, hapten- and mite-elicited models, exhibiting inhibitory effects comparable to that of tacrolimus^[1]. A single topical application of RVT-501 significantly inhibits spontaneous scratching during 1–2 h after application in mice with chronic dermatitis; the inhibition is partial and similar between 0.01% and 0.03%. Topical application of 0.03% RVT-501 to the rostral back significantly inhibits the increased activity of the cutaneous nerve in mice with chronic dermatitis. The cutaneous concentration of cAMP is significantly decreased in mice with chronic dermatitis, and this decrease is reversed by topical RVT-501 application^[2].

参考文献

[1]. Ishii N, et al. Antipruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model. J Pharmacol Exp Ther. 2013 Jul;346(1):105-12.

[2]. Andoh T, et al. Topical E6005, a novel phosphodiesterase 4 inhibitor, attenuates spontaneous itch-related responses in mice with chronic atopy-like dermatitis. Exp Dermatol. 2014 May;23(5):359-61.